期刊
PHARMACEUTICS
卷 13, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13122049
关键词
nasal delivery; brain-targeting; neurogenerative disorders; CNS disorders; nanotechnology; nanomedicine
The blood-brain barrier poses a challenge to delivering therapeutic molecules to the brain, but nose-to-brain drug delivery bypasses this barrier and increases drug concentration in the brain, improving treatment efficacy. Recent advances in nanotechnology have played a significant role in this area.
Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits the penetration of therapeutic molecules to the brain after oral or parenteral administration, which, in combination with hepatic metabolism and drug elimination and inactivation during its journey in the systemic circulation, decreases the efficacy of the treatment, requires high drug doses and often induces adverse side effects. Nose-to-brain drug delivery allows the direct transport of therapeutic molecules by bypassing the BBB and increases drug concentration in the brain. The present review describes mechanisms of nose-to-brain drug delivery and discusses recent advances in this area with especial emphasis on nanotechnology-based approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据